Blog
RSS FeedPosted by Michael Wonder on 14 Jun 2016
NICE recommends laser device to help thousands of men with an enlarged prostate
14 June 2016 - Thousands of men could benefit from laser treatment for an enlarged prostate as recommended in new guidance ...
Posted by Michael Wonder on 09 Jun 2016
NICE’s Eylea guideline ‘out of touch with clinical practice’
9 June 2016 - Bayer says it is disappointed that NICE is supporting NHS use of anti-VEGF therapy Eylea to treat ...
Posted by Michael Wonder on 03 Jun 2016
NICE publishes appraisal consultation for crizotinib (Xalkori) for patients with non-small-cell lung cancer
1 June 2016 - NICE has published an appraisal consultation document for crizotinib (Xalkori) for use by patients with non-small-cell ...
Posted by Michael Wonder on 03 Jun 2016
NICE publishes appraisal consultation for pirfenidone (Esbriet) for patients with idiopathic pulmonary fibrosis
3 June 2016 - NICE has published an appraisal consultation document for pirfenidone (Esbriet) for use by patients with idiopathic ...
Posted by Michael Wonder on 01 Jun 2016
NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund
1 June 2016 - NICE has published a second appraisal consultation document for ibrutinib for chronic lymphocytic leukaemia. ...
Posted by Michael Wonder on 26 May 2016
NICE issues draft guidance for necitumumab (Portrazza)
26 May 2016 - NICE has released an appraisal consulation document for necitumumab for untreated advanced or metastatic, squamous non-small-cell ...
Posted by Michael Wonder on 25 May 2016
NICE updates guidance on the use of cabazitaxel in patients with hormone-relapsed metastatic prostate cancer treated with docetaxel
24 May 2016 - This guidance replaces NICE technology appraisal guidance on the use of cabazitaxel in patients with hormone-refractory metastatic ...
Posted by Michael Wonder on 25 May 2016
NICE recommends three diabetes treatments
24 May 2016 - The three drugs can all be used on their own if a person can’t use metformin or ...
Posted by Michael Wonder on 20 May 2016
NICE recommends Novartis lung cancer drug Zykadia
20 May 2016 - NICE has recommended Novartis's Zykadia (ceritinib) for lung cancer in final guidance, after the manufacturer agreed to ...
Posted by Michael Wonder on 20 May 2016
Long term benefits of breast cancer drug pertuzumab too uncertain says NICE in draft guidance
20 May 2016 - NICE has today issued draft guidance not recommending pertuzumab (Perjeta, Roche) to treat HER2-positive breast cancer because ...
Posted by Michael Wonder on 12 May 2016
NICE turns down Opdivo for lung cancer
12 May 2016 - It is looking likely that patients with the most common form of lung cancer will not be ...
Posted by Michael Wonder on 11 May 2016
NICE backs NHS use of Benlysta, five years after EU nod
11 May 2016 - The first new drug for patients with lupus in more than 50 years could soon be available ...
Posted by Michael Wonder on 09 May 2016
NICE backs use of AbbVie's Humira for hidradenitis suppurativa
9 May 2016 - Final draft guidance not in accordance with HTA agencies in France & Australia. ...
Posted by Michael Wonder on 07 May 2016
NICE draft guidance recommends new drugs for cholesterol disorder
5 May 2016 - NICE has today published final draft guidance recommending 2 new treatment options for some people who have ...
Posted by Michael Wonder on 29 Apr 2016
NICE recommends combined drug therapy proven to extend life for skin cancer
29 April 2016 - NICE is today recommending a new drug combination for melanoma that could extend life by six months. ...